Neoadjuvant Chemoradiotherapy vs Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
J. Clin. Oncol 2022 Jan 27;[EPub Ahead of Print], E Versteijne, JL van Dam, M Suker, QP Janssen, K Groothuis, JM Akkermans-Vogelaar, MG Besselink, BA Bonsing, J Buijsen, OR Busch, GM Creemers, RM van Dam, FALM Eskens, S Festen, JWB de Groot, B Groot Koerkamp, IH de Hingh, MYV Homs, JE van Hooft, ED Kerver, SAC Luelmo, KJ Neelis, J Nuyttens, GMRM Paardekooper, GA Patijn, MJC van der Sangen, J de Vos-Geelen, JW Wilmink, AH Zwinderman, CJ Punt, G van Tienhoven, CHJ van EijckFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.